Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease

Sanifit announces that it will start a new clinical development program to investigate the effect of SNF472 in End Stage Kidney Disease (ESKD) patients with Peripheral Artery Disease (PAD), a cardiovascular disease affecting peripheral arteries by reducing blood flow to the limbs.

VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants

Ysios Capital co-leads EUR 32 million Series B financing in VarmX.

CVRx® Raises $50 Million in New Equity Financing

CVRx, Inc. announced today that it raised $50 million to close its latest round of equity financing.

AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

AM-Pharma B.V. today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development.

SNF472 Mechanism of Action data published in British Journal of Pharmacology

Sanifit today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of Pharmacology (BJP).

Ona Therapeutics raises €30M in Series A financing

Ysios Capital invests in Ona Therapeutics 30M€ round.

Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020

AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation.

CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting

Ysios Capital presents its third fund of € 200M

The team has been strengthened with five Venture Partners to support the evaluation of potential investments.

Sanifit Enhances Leadership Team with New Executive Appointments